Reproductive Techniques, Assisted Clinical Trial
Official title:
Prospective, Randomized Open Trial to Evaluate the Efficacy of Highly Purified Urinary FSH Versus Recombinant FSH in Oocyte Donors Undergoing Controlled Ovarian Stimulation Based on Receptor N680S FSH Gene Polymorphism. Genodon Trial
Exploratory, prospective, randomized, comparative, open trial with control group treated to assess whether the effective use of urinary FSH (uFSH) or recombinant FSH (rFSH) can be influenced by genotype of receptor N680S FSH Gene Polymorphism.
The aim of this study is to determine whether the number of oocytes obtained in women oocyte
donors may be different with the use of rFSH or uFSH based on receptor N680S FSHR gene
polymorphism.
This is an exploratory, prospective, randomized, comparative, open trial with control group
treated according to the usual therapeutic approach in our institution for ovarian
stimulation for oocyte donors prospective exploratory study control group .
Three groups will be set based on follicle-stimulating hormone receptor (FSHR) genotype for
the polymorphism N680: Group SS (Ser/Ser), group SN (Ser/Asn) and group NN (Asn/Asn). Donor
members of each group will be randomly assigned to receive daily 225 IU of recombinant or
urinary FSH for controlled ovarian stimulation protocol with antagonists. To avoid
unintentional bias, allocation to treatment group will take place at the time in which
ovarian stimulation according begins with a list of random allocation of treatments for each
of the groups (SS , SN and NN) that will be associated the code of the patient and are
prepared and will be available before the start of the study. The code assignment and
treatment of the patient will consecutively in the order of the list and must be recorded in
the medical history of the patient. The next scheduled patient will be assigned to the code
and the next immediate treatment in this list.
The protocol for controlled ovarian stimulation in oocyte donors, will be performed always
according to the usual protocol in the Instituto Bernabeu.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05442125 -
First Live Birth Rate With eSET After Preimplantation Methylome Screening (PIMS) Versus Conventional In-vitro Fertilization
|
N/A | |
Withdrawn |
NCT00767611 -
Molecular Markers of Human Sperm Function
|
N/A | |
Completed |
NCT04549649 -
The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response
|
N/A | |
Completed |
NCT02457481 -
An Alternative Culture Medium to Better Support Preimplantation Embryo Development in Vitro
|
N/A | |
Completed |
NCT02567552 -
Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone
|
Phase 4 | |
Completed |
NCT00518141 -
Use of Acetyl Salicylic Acid and Terbutalin in Assisted Reproductive Techniques (ART)
|
N/A | |
Terminated |
NCT01071200 -
Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle
|
Phase 3 | |
Recruiting |
NCT02516462 -
In Vitro Maturation of Human Eggs
|
N/A | |
Recruiting |
NCT05473039 -
Effect of a Multivitamin Supplement With Probiotic (Seidivid Ferty4®) on Oocyte Retrieval and Quality
|
N/A | |
Recruiting |
NCT04124913 -
Oral Dydrogesterone vs. Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles
|
Phase 4 | |
Completed |
NCT02381821 -
Endometrial Volume and Sub-endometrial Vascularity as Predictors of In-vitro Fertilization Success
|
N/A | |
Active, not recruiting |
NCT02625532 -
Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles (LUTEAL Trial)
|
N/A | |
Completed |
NCT04458454 -
"Study of the Effects of Serum and Follicular Fluid Relaxin Levels on Ovarian Function in IVF Cycles"
|
||
Active, not recruiting |
NCT03901170 -
Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle?
|
Phase 4 |